BioMedNewsBreaks

FridaySep 19, 2025 9:50 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Closes $375,000 Private Placement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based products for more accurate breast cancer screening, diagnosis and treatment, announced it has closed a non-brokered private placement of 1.5 million units at $0.25 per unit for gross proceeds of $375,000. Each unit includes one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. An insider acquired 100,000 units under exemptions from MI 61-101 requirements, and the company paid $3,500 and issued 14,000 broker warrants exercisable at $0.25 for three years in connection with the offering.…

Continue Reading

FridaySep 19, 2025 9:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth.” The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature underscores how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential. To view…

Continue Reading

ThursdaySep 18, 2025 9:45 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research

Oncotelic Therapeutics (OTCQB: OTLC) today announced its placement in an editorial published by NetworkNewsWire (“NNW”) titled “Advancing Cancer Research Brings New Hope for Patients Worldwide.” The article highlights the urgent need for innovation in treating deadly cancers such as glioblastoma and pancreatic cancer, as well as rare pediatric disorders. Under the leadership of chair and CEO Dr. Vuong Trieu, Oncotelic is leveraging AI, nanomedicine and advanced clinical strategies to build a transformative pipeline. Backed by an intellectual property portfolio that includes approximately 500 patent applications and 75 granted patents, the company aims to reshape treatment approaches for cancer and rare…

Continue Reading

ThursdaySep 18, 2025 9:15 am

BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer 

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (‘NSCLC’) patients,” reads a recent article. “Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence,” Lantern Pharma CEO and President Panna Sharma was quoted as saying. “This achievement builds…

Continue Reading

TuesdaySep 16, 2025 10:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early signs of antitumor activity. The open-label study in 63 patients with advanced relapsed or refractory solid tumors, including GBM, demonstrated disease control in 48% of evaluable patients at therapeutic dose levels, with notable responses in DDR-deficient cancers such as NSCLC, colon cancer, thymic carcinoma, and GIST. No dose-limiting toxicities were observed, and adverse events were predominantly mild. Lantern plans to advance LP-184 into Phase 1b…

Continue Reading

TuesdaySep 16, 2025 9:50 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches FAQ Page to Enhance Transparency and Investor Engagement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the detection and treatment of breast cancer, has launched a new Frequently Asked Questions page on its corporate website at www.izocorp.com/faq. The resource provides accessible information on the company’s IzoView Breast CT Imaging System, development milestones, and competitive positioning, addressing topics such as breast density, imaging workflow, and comparisons with other modalities. Optimized for search and AI platforms, the FAQ page supports Izotropic’s investor relations, clinical outreach, and advocacy initiatives. To view the full press release, visit https://ibn.fm/Q0trn About Izotropic More information about Izotropic Corporation can…

Continue Reading

TuesdaySep 16, 2025 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial Highlighting Innovative Therapeutics Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth” (https://ibn.fm/WpGOO). The piece spotlights Oncotelic’s leadership in RNA-based, immunotherapy, and targeted therapeutics, addressing critical unmet needs in aggressive cancers and pediatric rare diseases. Led by chair and CEO Dr. Vuong Trieu, the company is advancing a portfolio supported by more than 500 patent applications and 75 issued patents, leveraging AI, nanomedicine, and novel clinical models to transform cancer and rare disease treatment. To view the full press release, visit https://ibn.fm/O3Zk7 About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a…

Continue Reading

FridaySep 12, 2025 12:36 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs 

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, announced a summary of major accomplishments achieved over the past two years. The update highlights progress across multiple late-stage programs, including OT-101, now in Phase 3 for pancreatic cancer with additional applications in ARDS/COVID-19, and OXi4503, advancing from Phase 2 in AML/MDS toward pivotal Phase 3 design. Other assets include CA4P/Fosbretabulin, AL-101 for Parkinson’s disease and sexual dysfunctions, AL-102 in discovery for Alzheimer’s disease, pediatric rare disease programs with potential Priority Review Vouchers, and a nanomedicine pipeline advancing several 505(b)(2) drug candidates. CEO Dr. Vuong Trieu…

Continue Reading

FridaySep 12, 2025 9:25 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Expands IP Portfolio with New U.S. Patent Filings

HealthLynked (OTCQB: HLYK), a leader in patient-centric healthcare technology, announced the submission of two new U.S. patent applications covering a Universal Patient Identifier (UPIN) system designed to unify health records without relying on Social Security numbers and an AI Appointment Scheduling Agent capable of multilingual, personalized booking across providers, specialties, and insurance networks, further strengthening the company’s intellectual property portfolio and advancing its mission to secure medical data access, streamline care coordination, and enhance patient experience. To view the full press release, visit https://ibn.fm/cUoXt About HealthLynked Corp HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs.…

Continue Reading

ThursdaySep 11, 2025 9:20 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the more accurate screening, diagnosis and treatment of breast cancers, announced its sponsored placement in a MarketScreener.com editorial titled From Healthcare to Automation: Investing In Next AI Wave. The article discusses the growing adoption of specialized AI applications across industries and features Izotropic’s IzoView technology as a rare early-stage medtech opportunity with the potential to establish a new standard of care in breast cancer imaging. To view the full press release, visit https://ibn.fm/OOA6A About Izotropic: More information about Izotropic Corporation can be found on its corporate…

Continue Reading